Bio Plus Co

Bio Plus Co Operating Cash Flow

The Operating Cash Flow of Bio Plus Co (099430.KQ) as of Oct 21, 2026 is 14.74 B KRW. In the previous year, Operating Cash Flow was 22.29 B KRW — a change of -33.88% (lower).

Operating Cash Flow

14.74 BKRW

YoY

-33.88%

Last updated:

Operating Cash Flow of Bio Plus Co is 2025 14.74 B KRW. Operating Cash Flow of Bio Plus Co was 2024 22.29 B KRW. It decreases by -33.88% lower compared to the previous year.

The Bio Plus Co Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
3.15 B KRW
Jan 1, 2019
4.96 B KRW
Jan 1, 2020
10.04 B KRW
Jan 1, 2021
13.35 B KRW
Jan 1, 2022
13.36 B KRW
Jan 1, 2023
16.04 B KRW
Jan 1, 2024
22.29 B KRW
Jan 1, 2025
14.74 B KRW
The Bio Plus Co Operating Cash Flow history
YEAROperating Cash FlowYoY
14.74 BKRW-33.88%
22.29 BKRW+38.96%
16.04 BKRW+20.07%
13.36 BKRW+0.05%
13.35 BKRW+32.95%
10.04 BKRW+102.34%
4.96 BKRW+57.63%
3.15 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

Operating Cash Flow of Bio Plus Co is 14.74 B KRW in 2025.

Operating Cash Flow of Bio Plus Co changed from 22.29 B KRW to 14.74 B KRW, representing a -33.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Bio Plus Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Bio Plus Co

All Key Metrics — Bio Plus Co